Intraperitoneal dissemination of disease is an important cause of morbidity and mortality among women with genital tract cancers. In 1956, Keettel and Elkins (/) proposed cytologic examination of intraoperative peritoneal washings as a means of detecting subclinical metastases. Subsequently, peritoneal washing cytology (hereafter referred to as "peritoneal cytology") has been adopted as part of the surgical work-up of such patients. In 1971, Creasman and Rutledge (2) reported that peritoneal cytologic results correlated well with prognosis in ovarian, endometrial, and cervical cancers.
Our interest in this subject began when we observed cytologic patterns in peritoneal washings that were not observed in spontaneous effusions (3). We systematically analyzed our case patients and paid close attention to histologic correlation and possible pitfalls in interpretation (4j). We found that the sensitivity of peritoneal cytology was less than what we had anticipated from the earlier literature (5). We were also surprised that few case patients had cytology as the only evidence of intraperitoneal involvement (5) .
In this report, we update our results on epithelial gynecologic cancers from the perspective of long-term follow-up and examine the overall clinical utility of intraoperative peritoneal cytology in gynecologic cancer.
Subjects and Methods
The peritoneal washings were collected routinely at the stan of exploratory laparotomies for suspected gynecologic neoplasms at University . Washings collected during surgeries for "second look" or clinical recurrence as well as those from procedures for nonepithelial tumors or metastases from nongenital primary tumors were excluded from this study. The number of washings performed varied with the pnmary site of the tumor and ranged from five for ovarian cancer cases and three for endometrial cancer cases to one for cervical cancer cases. The cytopreparation for these samples (4S) and the correlation between cytologic and histologic findings for some of the cases included in this study have been reported previously (5.6). Briefly, 100 mL of a sterile saline solution was instilled into the peritoneal cavity immediately after peritonea] entry and lysis of adhesions. The fluid was then aspirated and sent to the cytology laboratory for analysis. Treatment was individualized for each patient by use of standard therapies at the time of diagnosis. Followup data were obtained through the Tumor Registry at University Hospital-Stony Brook. The median follow-up was 57 months (range, 0-154 months).
The cytologic results reported here represent our original interpretations, made without knowledge of the results of patient follow-up. One positive washing was sufficient to classify a case as positive by cytology in this study. The criteria for malignancy used in these samples were adapted from the criteria used by Ziselman et al. (7) . Briefly, the cells in question had classical criteria for malignancy (including abnormal groups of cells and single cells, disordered nuclear arrangement, karyomegaly, and chromatin and nucleolar abnormalities), were outside the morphologic spectrum of reactive mesothelial cells and benign surface reactions (3, 4) , and resembled cells of the patient's primary tumor. Peritoneal histology was considered to be positive when histologic sections of any organs showed tumor involving the serosal surface or when any intraperitoneal biopsy specimen contained histologically detectable tumor. Because the morphologic spectrum of female genital tract tumors is extremely heterogeneous, the washings from cases thought to be abnormal were compared with the histologic sections of the primary tumor before final interpretation. Histologic correlation was helpful in identifying some cases that would otherwise have been misclassified (5 . C = peritoneal washing cytology; H = peritoneal histology. tFor purposes of this comparison, C+ H+ = true positive, C-H-= true negative, C-H+ = false-negative, and C+ H-= false positive using peritonea] histology as the standard; however, for diagnostic purposes, C+ H-is considered true positive. PVPR = predictive value of a positive peritoneal washing cytology; PVNR = predictive value of a negative peritoneal washing cytology. carcinoma and one with cervical carcinoma) died of their cancer 11-34 months after surgery.
The cytologic findings and follow-up data are shown in Table 2 . In general, for each body site and FIGO stage, patients with negative cytology samples survived longer than those with positive samples. Results for the individual primary sites are analyzed more fully below.
Ovarian Carcinomas
For the 112 patients with ovarian carcinoma ( (Table 2) . Five-year survival for ovarian cancer patients with negative cytology was 65.0% (95% confidence interval [CI] = 43.7%-86.3%) compared with 9.2% (95% CI = 3.3%-15.1%) for those with positive cytology. For patients with stage I disease, 5-year survival was 82.0% (95% CI = 48.7%-100%) among those with negative cytology and 20% (95% CI = 0-55.3%) with positive cytology. It is interesting that, for patients with stage III ovarian cancers, 5-year survival was 55.6% (95% CI = 18.4%-92.8%) in those with negative cytology and 7.6% (95% CI = 0.6%-14.7%) in those with positive cytology.
Kaplan-Meier survival analysis for the pooled (all stages) population of patients with ovarian carcinomas (Table 2) showed significant differences based on cytologic status after adjustment for stage (f<.01). Significant survival differences were also demonstrated for patients with stage I (Fig. 1, A) , III (Fig. 1, B) , or IV ovarian cancers, but not for three patients with stage II cancers. It is interesting that Kaplan-Meier analysis for patients with stage III disease indicated a 90-month mean survival (95% CI = 62-117 months) for seven patients (10.4%) with negative cytology results for peritoneal washings out of a total of 67, compared with a 21-month mean survival (95% CI = 16-26 months) for 60 patients with positive results
Borderline Ovarian Tumors
Cytology was positive in five patients (31.2%) with borderline (of low malignant potential) ovarian tumors. These patients included two of 11 with stage I disease, two of four with stage III disease, and one of one with stage IV disease.
None of the 16 patients with borderline tumors died during a follow-up period ranging from 68 to 154 months (Table 2 ). These patients included seven patients (43.8%) who had cytologic and/or histologic evidence of intraperitoneal disease at initial surgery (Table 1, A) .
Endometrial Carcinomas
The results obtained in 135 endometrial cancer patients, including four (3.0%) who had preoperative radiation therapy, are shown in Table 2 (Table 2 ) revealed significant differences in survival when factored for cytologic diagnosis {P<.QQ\). This difference was maintained in patients with stage I (Fig. 2, A) or II disease, but not in the few patients with stage III (n = 9) or IV (n = 4) disease. The median survival was 8 months (95% CI = 3-13 months) for patients with positive cytology (Table 2) , and the mean followup was 128 months (95% CI = 118-137 months) for patients with negative cytology-
Cervical Carcinomas
Overall, eight (8.7%) of 92 cervical cancer patients (Table 2 ) had positive washings. These patients included 5.2% of 77 patients with stage I disease, 10.0% of 10 patients with stage II disease, 50.0% of four patients with stage III disease, and the one patient with stage IV disease. One (25.0%) of four patients with stage I disease with positive cytology had no histologic evidence of peritoneal involvement. All patients with positive cytology died of cervical cancer (median survival, 7 months), whereas the mean follow-up was 108 months (95% CI = 95-129 months) for those with negative cytology. Five-year survival was 69.5% (95% CI = 59.1%-79.6%) for patients with negative cytology, whereas no patient with positive cytology survived 5 years. Patients with stage I disease with negative cytology had a 76.3% (95% CI = 66.0%-86.5%) 5-year survival rate.
Kaplan-Meier survival analysis for the 92 cervical cancer patients (Table 2 ) revealed significant differences according to cytologic status after adjustment was made for stage (/><.001). Significant differences were also found for patients with stage I (P<.001) (Fig. 2, B) or II (P<.01) disease but not for the few patients with stage III (n = 4) or IV (n = 1) disease.
Discussion
Peritoneal washing cytology evolved in an attempt to explain intraperitoneal recurrences of female genital tract cancers following curative resections (7, 5, 9) . The enhanced sensitivity of cytology to detect subclinical intraperitoneal metastases was assumed, as was the poor prognosis implicit in this finding. Although earlier studies {8-12) supported this approach, critical evaluation of the results of those studies does not indicate rigorous testing of that hypothesis. Cytologic criteria for malignancy were often not stated, correlation with peritoneal histology was generally incomplete or not mentioned, and length of patient followup, if reported, was generally short. Creasman and Rutledge (2) supported the unfavorable prognostic implications of malignant peritoneal cytology, but they did not address the sensitivity of this test, except in relation to gross intraperitoneal disease. Only in recent years has there been significant effort to define the cytologic criteria and diagnostic pitfalls in these samples (3-7, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The factors that present diagnostic dilemmas in these specimens have been summarized elsewhere (4); they include polymorphic mesothelial cells (3,4,7,8J5,17J8Jl-24) , endosalpingiosis (benign miillerian inclusions) (3, 4, 13, 16, [18] [19] [20] [21] , and endometriosis (ectopic benign endometrial tissue) (3, 18) . There is concern that one of these factors could be misinterpreted to be an intraperitoneal carcinoma in a patient with localized cancer (4, 15, 1920) .
In our series, the cytology results were strongly associated with total survival for patients with epithelial cancers of the ovary, endometrium, and cervix, even after we adjusted for stage. However, in contradistinction to the original rationale for peritoneal washings, positive cytology was rarely the sole indication of intraperitoneal tumor in our patients.
Ovarian Tumors
As in other series (9, 11, 12) , ovarian cancer patients had the highest percentage of malignant peritoneal cytology, reflecting the tendency for ovarian cancer to present at advanced stage. It is notable that our data suggest that cytology results stratified survival within the stages that had sufficient cases for comparison. (Although we did not control for therapy, ovarian cancers with peritoneal extension were treated according to protocols then considered to be standard-typically, cyclophosphamide, cisplatin, and doxorubicin.) On the other hand, patients with borderline ovarian tumors had excellent survival, regardless of cytologic status. Previous reports (3-5,7,J 7-20) have noted the difficulty in distinguishing between endosalpingiosis, serous tumors of low malignant potential, and well-differentiated serous carcinoma on cytologic samples. From the survival data in this study, the clinically significant question appears to be distinguishing endosalpingiosis and borderline tumors from carcinoma. We relied on the histologic diagnosis to subclassify the biologic potential of ovarian tumors as malignant or borderline with good success. More difficult is the issue of distinguishing endosalpingiosis from metastatic tumor in the washings from a patient with stage I ovarian serous carcinoma. Comparison of the cells in the peritoneal washing with the histology or touch imprints of the primary tumor is helpful. We would be reluctant to make an interpretation of malignancy if 1) the problematic cells were present solely as cohesive groups, 2) the groups were sparse (one to two groups per slide), 3) the cells met the published criteria of endosalpingiosis (13) (14) (15) (16) (17) 19, 20) , 4) the tumor did not involve the serosal surface, and 5) there was no intraperitoneal tumor rupture. Histologically documented endosalpingiosis or endometriosis in such a patient would be an additional reason to exercise caution.
Endometrial Carcinomas
The value of peritoneal washings in endometrial carcinoma has been highly controversial (2, . While some studies (2 25 J26J1J2 36,41,47) report good correlation of cytology with prognosis, other studies 44) do not. The fact that the reported rate of malignant peritoneal washings in clinical stage I endometrial cancer has varied widely, from 5.0% to 29.8% (926-3739,40) , is reflective of this problem. In our series, positive cytology occurred late in the evolution of endometrial cancer and was associated with histologically detected tumor outside the uterus. None of our 17 endometrial cancer patients with positive peritoneal cytol-ogy had pathologic stage I disease. Although it is possible that transtubal migration (9^7^5,38) or subclinical lymphatic permeation (33J8) into the peritoneal cavity can occur early, we found no evidence to cite these mechanisms. We therefore believe that this occurrence is uncommon. On the other hand, we have observed endosalpingiosis (5), endometriosis (Zuna RE: unpublished observation), and salpingitis (Zuna RE: unpublished observation) as presenting diagnostic dilemmas in occasional cases in which endometrial carcinoma was histologically confined to the uterus. Yazigi et al. (27) suggested that manipulation accompanying preoperative intracavitary radiation therapy could dislodge endometrial cancer cells into the fallopian tubes and peritoneal cavity. However, mesothelial atypia associated with radiation therapy has also caused diagnostic problems (5, 18, 23) . Since few of our patients received preoperative radiation therapy, we are unable to address this issue.
Cervical Carcinomas
Because cervical cancer remains retroperitoneal until late in its progression (2) and most cervical cancers present at an early stage, cervical cancer patients have the lowest percentage of positive peritoneal cytology, varying from 7.0% to 21.0% (6, [48] [49] [50] [51] [52] [53] . However, all of our patients who had stage I disease as well as positive washings had short-term survival and eventually died of their cancer. As with patients in other studies (48^0^3), these patients had other indicators of high risk, such as bulky disease. Cytology, however, may be the only indication of peritoneal extension in some patients with stage I disease (6).
Role of Peritoneal Washings
Because of our findings, we question the role of peritoneal washing cytology as a sensitive indicator of peritoneal extension in early stage female genital tract cancer. While there are surely cases in which surgical exploration occurs during the interval in which only microscopic tumor has penetrated into the peritoneal cavity, intuitively, it would seem that these cases would be uncommon. Nonetheless, we believe that peritoneal washings can continue to have an important role in serving as 1) a control for the thoroughness of the exploratory procedure, 2) a means of stratifying patients in terms of prognosis over that predicted by stage, and 3) a biologic marker for developing optimal therapy for intraperitoneal disease. These issues are briefly discussed below.
Control for the exploratory process. In one patient with endometrial cancer who was thought to have negative peritoneal histology, positive cytology prompted us to review the gross specimen and subsequently to document serosal implants. Under circumstances in which the peritoneal exploration is limited, cytology could detect peritoneal extension that would otherwise have been overlooked. Thus, peritoneal washings can function as a control for the staging process while adding scant minutes and minimal cost to the procedure. We believe, however, that washings should be used in conjunction with a thorough peritoneal exploration. This should include liberal use of biopsies of suspicious areas that could document endosalpingiosis or endometriosis.
Prognosis. For each primary site, cytologically detected intraperitoneal extension by carcinomas in this series was associated with a dismal prognosis. Although some investigators (23^24^27, 40) have reported only limited correlation between peritoneal washing results and survival, our data suggest that peritoneal cytology findings correlate with risk for recurrence and death due to cancer above that indicated by stage alone. In patients with stage III ovarian cancer, for example, those who had negative washings had longer survival than those in whom cytology was positive. We cannot exclude that differences in tumor burden in the patients with stage III disease can account for these survival differences, but all patients with stage III disease had a histologically verified tumor in the peritoneal cavity. Creasman and Rutledge (2) also reported longer survival associated with negative cytology in patients with grossly evident peritoneal tumors when compared with those with positive cytology. While a case-control study with standardized therapy is needed, it is conceivable that there is a difference in biologic potential in tumors that establish an ascites phase and those that elicit a fibrogenic host response that enmeshes the tumor cells. The greater propensity of cervical adenocarcinomas than squamous cell cancers to develop ascites (6$4) may be evidence for such a biologic phenomenon.
Biologic marker for research in intraperitoneal therapeutics. We have previously observed that intraperitoneal extension may be a biologically significant event in disease progression that poses unique therapeutic challenges (6). Although positive peritoneal cytology is usually accompanied by other indications of advanced disease, we believe that reliable documentation of this phenomenon will help to determine optimal therapy to control intraperitoneal carcinomatosis. It was not possible in this study to show that therapeutic intervention increases survival in patients with positive cytology. However, we are hopeful that documentation of cytologically detected malignant cells within the peritoneal cavity will enhance the stratification of patients and assist in the development of effective therapy for these patients.
Finally, we believe that any case should be critically reviewed if chemotherapy or radiation therapy is contemplated solely on the basis of positive peritoneal cytology. This review should consist of 1) comparison of the cells in the washing with the histology of the primary tumor, 2) correlation of pathologic data with the clinical findings in the peritoneal cavity at exploration, and 3) reevaluation of the gross surgical specimen^) if possible. We endorse the use of peritoneal washing cytology in laparotomies for female genital tract cancers as long as the above-mentioned safeguards against false-positive interpretations are in place.
